HIP0612

HIP0612 is an investigational drug developed for the treatment of gastric ulcers. It is currently being evaluated in phase 3 clinical trials to assess its efficacy and safety in patients with active gastric ulcers. The drug is administered once daily, either alone or in combination with HPP2202, over a period of 4 or 8 weeks. While detailed information about its mechanism of action and molecular class has not been disclosed publicly, HIP0612 represents a novel therapeutic approach aimed at improving outcomes for patients suffering from gastric ulceration[1][2][3][4]. The developer, Hanmi Pharmaceutical Company Limited, is known for advancing innovative therapies across multiple therapeutic areas.